1998 update on antiphospholipid antibodies.
The field of antiphospholipid antibodies continues to evolve, with major contributions from both clinical research and laboratory studies. Antiphospholipid antibodies remain one of the more common causes of acquired hypercoagulability, both in patients with systemic lupus erythematosus and in patients who have no known connective tissue disease. In recent years, great progress has been made in identifying the protein targets. In addition, knowledge of the clinical syndrome that we call antiphospholipid antibody syndrome has also progressed. Finally, new insights into treatment continue to be gained from clinical trails.
Petri
M
M
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
D017152:Antibodies, Antiphospholipid / Q000276:immunology / Q000502:physiology*; D001778:Blood Coagulation Disorders / Q000276:immunology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D012219:Rheumatology / Q000639:trends*; D016036:Seroepidemiologic Studies
D017152:Antibodies, Antiphospholipid